These findings contribute to better understand the tumour suppressor role of BRCA1 and the regulation of another tumour suppressor FOXO3 in breast cancer, and suggest FOXO3 as a diagnostic marker and therapeutic target for BRCA1-deficient basal-like breast cancer. This evidence concerns the gene FOXO3 and neoplasm.